Background: In the United States, estrogen replacement therapy ERT is discouraged in breast cancer survivors because of concerns that hormones may reactivate the disease. Because ERT can improve quality of life and decrease morbidity from osteoporosis and cardiovascular disease, however, this policy is increasingly being challenged.
Methods: From February to August 1995, 607 breast cancer survivors were interviewed concerning ERT usage. Sixty-four patients indicated they received some form of ERT after their breast cancer diagnosis. Medical records for these patients were analyzed for disease stage, surgical treatment, adjuvant treatment, estrogen and progesterone receptor status, date of initiation of ERT, type of ERT, recurrence, and final outcome. Patients receiving ERT were followed prospectively.
Results: Eight patients were excluded because they had used only vaginal cream ERT. The remaining 56 received ERT as conjugated estrogens, an estradiol patch, estropipate, or birth control pills. The median follow-up from diagnosis was 12.8 years range, 4.7–38.9 years. The median time on ERT since diagnosis was 6.4 years range, 1.0–20.9 years; 38% of the patients initiated ERT within 2 years of diagnosis. Estrogen receptors were positive in 28 74% of the 38 cases with available information. Pathological disease stage at time of diagnosis and treatment was 0 in 15 cases 27%, I in 27 48%, and II in 14 25%. Twenty-six patients 47% received adjuvant chemotherapy or hormonal therapy. One local recurrence and one contralateral breast cancer occurred during the follow-up period 13.5 and 9.6 years, respectively, with no regional or distant recurrences, for a 15-year actuarial disease-free survival rate of 92.5%. There were no breast cancer deaths.
Conclusions: Use of ERT in a cohort of breast cancer survivors with tumors of generally good prognosis was not associated with increased breast cancer events compared with non-ERT users, even over a long follow-up period.
Breast cancer Recurrence Estrogen replacement therapy Prognosis
This is a preview of subscription content, log in to check access.
Marchant DJ. Estrogen-replacement therapy after breast cancer. Risks versus benefits. Cancer 1993; 71(6 Suppl): 2169–76.PubMedGoogle Scholar
Spicer D, Pike MC, Henderson BE. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 1990; 4: 49–54.PubMedGoogle Scholar
Petitti DB, Perlman JA, Sidney S. Postmenopausal estrogen use and heart disease. N Engl J Med 1986; 315: 131–2.CrossRefGoogle Scholar
Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses’ Health Study. N Engl J Med 1991; 325: 756–62.PubMedCrossRefGoogle Scholar
Lindsay R. Estrogen therapy in the prevention and management of osteoporosis. Am J Obstet Gynecol 1987; 156: 1347–51.PubMedGoogle Scholar
Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 517–23.PubMedGoogle Scholar
Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA 1993; 269: 2637–41.PubMedGoogle Scholar
Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769–75.PubMedGoogle Scholar
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999; 17: 2365–70.PubMedGoogle Scholar
The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman’s Place. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998; 83: 1993–2000.Google Scholar
Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997; 65: 89–93.PubMedGoogle Scholar
Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985–90.PubMedGoogle Scholar
Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93.CrossRefPubMedGoogle Scholar
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–27.Google Scholar
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047–59.Google Scholar
Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women’s Health Study. JAMA 1999; 281: 2091–7.CrossRefPubMedGoogle Scholar
Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999; 17: 1482–7.PubMedGoogle Scholar
Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 1994; 16: 153–9.PubMedGoogle Scholar
Vassilopoulou-Sellin R, Klein MJ. Estrogen replacement therapy after treatment for localized breast carcinoma. Patient responses and opinions. Cancer 1996; 78: 1043–8.PubMedGoogle Scholar
Ganz PA, Greendale GA, Kahn B, O’Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy? Cancer 1999; 86: 814–20.PubMedGoogle Scholar
Marsden J, Sacks NPM. Hormone replacement therapy and breast cancer. Endocr Relat Cancer 1997; 4: 269–79.CrossRefGoogle Scholar
Powles TJ, Hickish T, Casey S, O’Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60–1.PubMedGoogle Scholar
Eden JA, Bush T, Nand S, et al. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995; 2: 67–72.Google Scholar
Decker DA, Pettinga JE, Cox TC, et al. Hormone replacement therapy in breast cancer survivors. Breast J 1997; 3: 63–68.Google Scholar
Peters GN, Jones SE. Estrogen replacement therapy in breast cancer patients: a time for change?[abst] Proc Am Soc Clin Oncol 1996; 15: 121a.Google Scholar
DiSaia PJ. Estrogen replacement therapy for the breast cancer survivor: a reappraisal. J Surg Oncol 1997; 64: 175–80.PubMedGoogle Scholar
Bluming AZ, Waisman JR, Dosik GM, et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer. Update III [abst]. Proc Am Soc Clin Oncol 1997; 16: 131a.Google Scholar
Ursic-Vrscaj M, Bebar S. A case-control study of hormone replacement therapy after primary surgical breast cancer treatment. Eur J Surg Oncol 1999; 25: 146–51.PubMedGoogle Scholar
Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 1999; 44: 186–92.PubMedGoogle Scholar
Fisher B, Anderson S, Redmond CK, Wolmark N, Wickerham DL, Cronin WM. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333: 1456–61.CrossRefPubMedGoogle Scholar